Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4352W HIGH $3.04
Volume
817.03 K
Value Traded
672.83 K
Short % Float
23.88%
-0.68%Week
-24.23%1 Month
-33.18%3 Month
-35.24%6 Month
-88.41%5 Year
-88.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
266.18 M
EPS (TTM)
-0.51
P/E Ratio
-
Ent. Value
146.47 M
Total Shares
181.08 M
Float Shares
122.90 M
Insiders
32.13%
Institutions
65.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IPSC Catalyst Timeline
Dated clinical, regulatory and corporate events for Century Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Century Therapeutics, Inc.
272Total events
5Upcoming
26Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationCNTY-813Presentation
Nonclinical data for CNTY-813 presented in oral presentation at EASD 2026
type 1 diabetessource ↗
●Management ChangeCorporate
Joseph Truitt appointed to Century Therapeutics Board of Directors
●Pre IND MeetingCNTY-813FDA Meeting
Completed pre-IND meeting with FDA for CNTY-813
type 1 diabetessource ↗
◆Oral PresentationCNTY-813Presentation
Oral presentation of CNTY-813 preclinical data at ADA 86th Scientific Sessions
type 1 diabetessource ↗
▲Oral PresentationCNTY-813Presentation
CNTY-813 preclinical data presented at ADA 2026
type 1 diabetessource ↗
●IND Enabling CompleteCNTY-308Preclinical
CNTY-308 in IND-enabling studies
B-cell-mediated diseasessource ↗
●IND Enabling CompleteCNTY-308Preclinical
CNTY-308 in IND-enabling studies
B-cell-mediated autoimmune diseasessource ↗
●Enrollment UpdateCNTY-101Trial
Patient enrollment ongoing for CNTY-101 in Phase 1/2 CARAMEL IST
autoimmune diseasesource ↗
▲Equity OfferingCorporate
Completed oversubscribed $135 million private placement financing in January 2026
▲Oral PresentationCNTY-813Presentation
CNTY-813 preclinical data presented at ADA 2026
type 1 diabetessource ↗
◆Trial InitiationCNTY-101Trial
Expansion to EU sites expected in 2025
B-cell mediated autoimmune diseasessource ↗
▲Enrollment CompleteCNTY-101Trial
Patient enrollment ongoing for CNTY-101 in Phase 1/2 CARAMEL IST in autoimmune disease
autoimmune diseasesource ↗
◆Oral PresentationPresentation
Fireside chat at Piper Sandler 37th Annual Healthcare Conference
◆Oral PresentationPresentation
State of the Art in Cell Therapy panel discussion at Piper Sandler 37th Annual Healthcare Conference
●IND Enabling CompleteCNTY-813Preclinical
Initiate IND-enabling studies by year-end 2025
Type 1 diabetessource ↗
◆IND Enabling CompletePreclinical
Anticipate initiating IND-enabling studies by end of 2025
type 1 diabetessource ↗
◆Topline ReadoutCNTY-101Clinical Data
Clinical data for CNTY-101 expected by end of 2025
autoimmune diseasesource ↗
▲Preclinical PoCCNTY-813Preclinical
Compelling preclinical data generated for CNTY-813
Type 1 diabetessource ↗
▲Preclinical PoCPreclinical
iPSC-derived beta islet program preclinical data package generated
type 1 diabetessource ↗
◆Oral PresentationPresentation
Century Therapeutics to present at Chardan's 9th Annual Genetic Medicines Conference
◆Oral PresentationPresentation
Management available for investor meetings at H.C. Wainwright conference
◆Oral PresentationPresentation
Century Therapeutics presentation at H.C. Wainwright 27th Annual Global Investment Conference
●Enrollment UpdateCNTY-101Trial
Patient dosing ongoing in CALiPSO-1 trial
B-cell-mediated autoimmune diseasessource ↗
●Development Candidate NominationPreclinical
Rapid progress toward drug candidacy for non-immune cell program
◆Topline ReadoutCNTY-101Clinical Data
Updated clinical data from ELiPSE-1 trial expected by mid-2025
B-cell malignanciessource ↗
◆Poster PresentationCNTY-101Presentation
Poster tour presentation on CNTY-101 preclinical data at EULAR 2025
B cell-driven autoimmune diseasessource ↗
◆Poster PresentationPresentation
Poster tour presentation on iPSC-derived CAR-NK, γδ CAR-T, and αβ CAR-T cells at EULAR 2025
B cell-mediated autoimmune diseasessource ↗
●IND Enabling CompleteCNTY-308Preclinical
On track to initiate IND-enabling studies for CNTY-308 in mid-2025
◆Trial InitiationCNTY-101Trial
Investigator-initiated Phase 1/2 trial CARAMEL to commence in mid-2025
B-cell mediated autoimmune diseases (systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, diffuse cutaneous systemic sclerosis)source ↗
◆Oral PresentationPresentation
Oral presentation on generation of iPSC-derived CD4+ and CD8+ CD19 CAR ab T cells
cancersource ↗
▲First Patient DosedCNTY-101Trial
Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease
autoimmune diseasesource ↗
◆Poster PresentationPresentation
Poster presentation on armoring iPSC-derived allogeneic therapies with TGF-b neutralizing synthetic receptor
solid tumorssource ↗
◆Oral PresentationPresentation
Live fireside chat on prioritized preclinical cell therapy programs
autoimmune diseases and cancersource ↗
◆Timing GuidanceCNTY-101Presentation
Expects to provide updated clinical data by mid-2025
r/r B-cell lymphomassource ↗
◆Pipeline PrioritizationCorporate
Pre-clinical pipeline prioritization to be announced in 1Q25
Past FDA Catalysts and PDUFA Decisions
How IPSC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-02 | CNTY-813 (iPSC-derived islet replacement therapy) | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$2M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 71%
Micro Cap(rank 469 of 660)
Percentile Rank
Century Therapeutics, Inc. faces pipeline headwinds (29/100), with $19M risk-adjusted pipeline value, led by CNTY-101 in Systemic Lupus Erythematosus (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTY-101 Monoclonal antibodyNCT06255028 | Systemic Lupus Erythematosus | Phase 1 | ACTIVE NOT_RECRUITING | 6 | Aug 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every IPSC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CNTY-101 | R/R B-cell lymphomas | Phase 1 | 2025-01-13 | 83% overall response rateRead More | January 2025 Corporate Overview 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities LitigatRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Russotti GregoryOfficer (See Remarks) | Sell | -2,587 509,198 held | $1.93 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IPSC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.4 % | 43.50 M | 17.75 M |
IPSC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IPSC ranks across every disease it competes in
Competitive Position is a premium feature
See how IPSC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIPSC News
IPSCCentury Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Century Therapeutics presented promising nonclinical data for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, at the EASD 2026. The data showed sustained glycemic control in diabetic mice and successful engraftment in rats. The company remains on track for an IND submission in Q4 2026, with initial clinical data expected in the second half of 2027.
Read more →IPSCCentury Therapeutics Appoints Joseph Truitt to Board of Directors
Century Therapeutics has appointed Joseph Truitt to its Board of Directors. Truitt, who has extensive experience in biotechnology leadership, will support the company's advancement of its iPSC-derived therapies. Notably, CNTY-813 is expected to submit an IND application in Q4 2026, while CNTY-308 is anticipated to enter clinical trials this year.
Read more →IPSCCentury Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Century Therapeutics has reported its second quarter 2026 financial results, highlighting a successful pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy aimed at treating type 1 diabetes. The company is on track for an IND submission in the fourth quarter of 2026. Preclinical data presented at ADA 2026 indicated that CNTY-813 achieved durable glucose control in vivo.
Read more →IPSCCentury Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
Century Therapeutics has announced that its CNTY-813 preclinical data will be presented at two major scientific congresses in 2026. The presentations will focus on CNTY-813, an iPSC-derived islet replacement therapy designed for type 1 diabetes, utilizing the company's Allo-Evasion™ technology. This therapy aims to provide durable engraftment without the need for chronic immunosuppression, addressing a significant limitation in current treatments.
Read more →IPSCNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Century Therapeutics presented promising preclinical data for CNTY-813, an iPSC-derived islet replacement therapy, at the ADA 2026. The therapy demonstrated durable glucose control for over eight months and maintained insulin secretion under immune pressure without the need for immunosuppression. The company is on track for an IND submission in Q4 2026 and expects initial clinical data in H2 2027.
Read more →IPSCCentury Therapeutics Reports First Quarter Financial Results and Business Updates
Century Therapeutics reported its first quarter financial results, highlighting progress in its pipeline, particularly CNTY-813 for type 1 diabetes, which is on track for an IND submission by Q4 2026. The company also plans to present preclinical data at the ADA annual Scientific Sessions in June 2026. Additionally, CNTY-308 is set to advance into clinical trials this year. Century's financial position is strong, with sufficient cash reserves to support operations until 2029.
Read more →IPSCCentury Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
Century Therapeutics, Inc. (NASDAQ: IPSC) announced that they will present preclinical data for CNTY-813 at the upcoming ADA 86th Scientific Sessions. This therapy aims to provide scalable, off-the-shelf islet cell replacements for patients with type 1 diabetes and significantly reduce the need for chronic immunosuppressive therapy. The oral presentation will take place on June 8, 2026, in New Orleans, Louisiana, highlighting the company's commitment to advancing this innovative therapy. Century's focus on patient access and efficacy reflects its ambitious goals for the future of diabetes treatment.
Read more →IPSC▼ -8.4%on this news
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
Century Therapeutics reported its 2025 financial results, highlighting progress in its lead program CNTY-813 for type 1 diabetes, with an IND submission expected in Q4 2026. The company also announced advancements in CNTY-308, a CAR-iT cell therapy, and secured $135 million in funding to support its operations into 2029. Despite a reduced cash position, Century remains optimistic about its pipeline and clinical prospects.
Read more →IPSCCentury Therapeutics to Participate in Upcoming Investor Conferences in March
Century Therapeutics, a biotechnology firm focused on iPSC-derived therapies, announced its participation in several investor conferences in March. The company aims to address autoimmune diseases and cancer through its innovative therapies. Live webcasts of the presentations will be available on their website, with archived replays accessible for 30 days.
Read more →IPSC▲ +5.2%on this news· ran to +19% by day 3
Unlocking the Value of our Pipeline for T1D January 2026 2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, T
Century Therapeutics is advancing their cell therapy pipeline focused on Type 1 Diabetes and other autoimmune diseases, with key programs CNTY-813 and CNTY-308 in IND-enabling studies. They are employing innovative Allo-Evasion technology aimed at enhancing therapeutic persistence and efficacy. The company has extended its cash runway to support its clinical milestones, with initial data expected by 2027. However, successful navigation of regulatory processes and associated risks remain critical to their future outcomes.
Read more →IPSC▲ +36.2%on this news· ran to +65% by day 3shared move
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes PHILADELPHIA
Century Therapeutics has announced an oversubscribed private placement financing of approximately $135 million to advance its lead program, CNTY-813, aimed at treating Type 1 diabetes. The investment will help extend the company's cash runway to the first quarter of 2029, with anticipation for an IND submission in 2026 and initial clinical data coming in 2027. The financing was led by new investor TCGX and included participation from other notable investors, emphasizing confidence in the company's innovative cell therapy approach.
Read more →IPSC▼ -5.7%on this news
Advancing Pipeline of Transformative Cell Therapies Corporate Deck – December 2025 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the
Century Therapeutics is advancing its pipeline of transformative cell therapies with several promising candidates approaching clinical trials. Key products include CNTY-101, CNTY-813, and CNTY-308, which are aimed at treating autoimmune diseases and B-cell-mediated conditions. The company boasts a well-established in-house manufacturing facility that significantly improves production efficiency and product quality. Preliminary trial data have shown positive early efficacy, particularly in B-cell depletion in patients with systemic lupus erythematosus. Century's innovative approaches, such as Allo-Evasion technology, hold potential for enhanced persistence of therapies in patients.
Read more →IPSCCentury Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors at a critical time for the company. Dr. Lee will serve on the Audit and Compensation Committees while Dr. Murphy will join the Compensation and Nominating Committees. Their extensive experience in biotechnology and corporate development is expected to support Century's efforts to advance its iPSC-derived cell therapies, including CNTY-813 for type 1 diabetes. The company's leadership anticipates that their appointments will help deliver significant value to patients and stakeholders.
Read more →IPSCCentury Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
Century Therapeutics, a biotechnology firm specializing in iPSC-derived cell therapies, will participate in the Piper Sandler 37th Annual Healthcare Conference in New York. Key executives, including Chief Scientific Officer Chad Cowan and CEO Brent Pfeiffenberger, will discuss advancements in cell therapy. They will also participate in a webcasted fireside chat, which will be available on the company's website. This event presents an opportunity for the company to showcase its innovative approaches in treating autoimmune diseases and cancer.
Read more →IPSC▼ -17.5%on this news
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Century Therapeutics reported its third quarter 2025 financial results, highlighting advancements in its iPSC-derived therapies. The company is focusing on its beta islet program for Type 1 Diabetes (T1D) and plans to initiate IND-enabling studies by the end of 2025. Additionally, CNTY-308 is set to enter clinical trials next year, supported by promising preclinical data.
Read more →IPSC▼ -17.5%on this newsshared move
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
Century Therapeutics has launched a new program, CNTY-813, targeting Type 1 diabetes using iPSC-derived beta islets. The therapy utilizes proprietary Allo-Evasion™ 5.0 technology to prevent immune rejection, aiming for durable glycemic control without immunosuppression. Preclinical data shows promise, with plans to initiate IND-enabling studies by the end of 2025 and submit an IND application by 2026.
Read more →IPSCCentury Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Century Therapeutics, a biotechnology firm specializing in iPSC-derived therapies, announced that its Chief Scientific Officer, Chad Cowan, will present at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025. The event will take place in New York, NY, and a live webcast will be available on the company's website. This presentation underscores the company's commitment to addressing autoimmune diseases and cancer through innovative therapies.
Read more →IPSCCentury Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference, with CEO Brent Pfeiffenberger leading the presentation. The event will take place in New York on September 9-10, 2025, and an on-demand webcast will be available starting September 5, 2025. This engagement highlights Century's commitment to advancing its iPSC-derived cell therapy pipeline.
Read more →IPSCCentury Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Century Therapeutics, Inc. has announced its financial results for Q2 2025 and provided a business update. The company continues to execute its clinical program for CNTY-101 in autoimmune diseases while also advancing preclinical studies for CNTY-308. Brent Pfeiffenberger has assumed the role of Board Chair, following a successful term by his predecessor. The firm aims to deliver clinical data for CNTY-101 within 2025, focusing on its innovative iPSC-derived cell therapies.
Read more →IPSCCentury Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
Century Therapeutics has announced two upcoming presentations at the EULAR 2025 Congress, scheduled for June 11-14, 2025, in Barcelona, Spain. The presentations will focus on their preclinical cell therapy pipeline, particularly CNTY-101, an iPSC-derived CAR-NK product targeting B cell-driven autoimmune diseases. These presentations aim to demonstrate the potential of their therapies in treating serious conditions.
Read more →About Century Therapeutics, Inc.
Headquarters25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA
BIOPHARMAWATCH ELITE PLUS
Trade the next IPSC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime